Acute myeloid leukemia (AML) treatment in Istanbul, Turkey
Acute myeloid leukemia is an aggressive, fast-growing leukemia of myeloid cells that needs prompt treatment. The usual path is intensive inductionchemotherapy — classically cytarabine with an anthracycline, the “7+3” regimen — to reach remission, followed by consolidation, with an allogeneic (donor) stem cell transplant a central curative option for many patients. Molecular testing for FLT3, IDH1/2 and NPM1 mutations decides whether targeted drugs are added. Istanbul hospitals offer this full pathway, often at JCI-accredited, state-authorized centers and well below Western-European prices for the same protocol. Every price we show is an illustrative placeholder until verified partner-hospital quotes exist — and you pay the hospital directly, never us. Start with a free 72-hour review of your reports before you decide anything.
What acute myeloid leukemia is
The U.S. National Cancer Institute describes adult acute myeloid leukemia (AML) as a cancer of the blood and bone marrow in which the marrow makes abnormal myeloid cells— the line that would normally become red cells, platelets and most white cells. Unlike the slow, watch-and-wait chronic leukemias, AML is acute: it grows quickly, crowds out healthy blood production, and, the NCI stresses, needs prompt treatment rather than delay. That is what sets it apart from its siblings across the wider leukemia family.
Diagnosis rests on blood counts, a bone-marrow aspirate and biopsy, and — crucially for AML — cytogenetic and molecular testing of the leukemia cells. The NCI notes that this testing, looking at chromosome changes and mutations such as FLT3, IDH1/2 and NPM1, both risk-stratifies the disease and identifies drug targets, which is why no two AML plans are quite alike. Browse the wider cancer types hub for related diagnoses.
Treatment options
The modalities the NCI lists for acute myeloid leukemia, and an honest note on each:
- Induction chemotherapy. The urgent first phase — classically cytarabine combined with an anthracycline, the “7+3” regimen — given in hospital to clear the marrow of leukemia and achieve a first remission. It is intensive and cannot usually wait.
- Consolidation. Once remission is reached, further chemotherapy cycles aim to destroy any leukemia the eye cannot see and keep the disease from returning. How much consolidation is given depends on the risk group the molecular testing places you in.
- Targeted & lower-intensity therapy. For specific mutations the NCI describes matched drugs — a FLT3 inhibitor such as midostaurin, or IDH1/IDH2 inhibitors — while venetoclax-based lower-intensity combinations are an option for older or unfit patients who cannot tolerate 7+3.
- Allogeneic stem cell transplant. A transplant of stem cells from a matched donor is a central curative option for many AML patients after remission, most often in intermediate- or high-risk disease. It is powerful but intensive, so whether it fits is decided case by case.
Honest note: AML is urgent and intensive, and fitness and mutation profile — not a fixed template — drive whether the plan is intensive chemotherapy plus a bone-marrow (stem cell) transplant or a lower-intensity, mutation-guided regimen. See how these approaches, including targeted therapy, chemotherapy and cellular therapies such as CAR T-cell therapy, work in general on the treatments & technology hub.
What it costs
There is no single AML price, because the cost is driven by the length of the intensive induction and consolidation hospital stays, the transfusions and anti-infective care needed through the low-blood-count weeks, whether targeted or lower-intensity drugs such as FLT3 or IDH inhibitors or venetoclax are added, and above all whether an allogeneic stem cell transplant is part of the plan — the transplant and its aftercare dominate the total. Every figure OncologyIstanbul™ publishes today is an illustrative placeholder pending verified partner-hospital quotes, and each is itemized so you can hold a real quote up against it line by line. See the Turkey Oncology Price Index or the full cancer treatment cost in Turkey breakdown.
The hospital, verified
We don’t show a wall of smiling hematologists or a “ranked” list — those are the easiest things to fabricate. Instead, you’re matched to one state-authorized Istanbul partner hospital whose hematology and stem cell transplant subspecialty fits your diagnosis, and you can verify its authorization against the Republic of Turkey Ministry of Health’s own records and its JCI accreditation in JCI’s public directory before you commit. Named specialist profiles appear only when a verified, consented physician is behind the name. See the full guide to cancer hospitals in Istanbul and how to check one yourself.
Where this fits
AML is one subtype within the broader leukemia treatment in Turkey overview, which itself sits inside the cancer treatment in Istanbul pillar. If you want your own reports read first, a free second opinion organizes and verifies your bone-marrow and molecular reports into a plain-language case file in your language before you decide whether to travel. Related modalities that often come up in AML care include immunotherapy and radiotherapy (used in some transplant conditioning).
Related cancers
Check everything here — us included
Common questions
Can I get AML treatment in Turkey?
Yes. Istanbul hospitals provide the full acute myeloid leukemia pathway the U.S. National Cancer Institute describes — urgent intensive induction chemotherapy to bring the disease into remission, consolidation to keep it there, targeted drugs matched to specific mutations, and allogeneic (donor) stem cell transplant when it is indicated, all backed by the transfusion and infection support the low-blood-count period demands. Because AML is fast-growing and needs prompt treatment, timing matters, so the honest thing to know is that induction usually cannot wait for lengthy travel arrangements. A free case review of your bone-marrow and molecular reports establishes what is confirmed and how urgent your situation is before you plan anything.
Why is molecular testing (FLT3, IDH, NPM1) so important in AML?
Because in AML the mutation profile chooses the drugs and predicts risk. Per the NCI, cytogenetic and molecular testing of the leukemia cells risk-stratifies the disease and identifies targets: FLT3 mutations can be treated with a FLT3 inhibitor such as midostaurin added to chemotherapy, IDH1 or IDH2 mutations have their own inhibitors, and markers such as NPM1 help gauge prognosis and monitor for residual disease. This is why AML cannot be treated from a template — two people with the same diagnosis may get different drugs. A case review flags whether this testing has already been done on your reports. This is general information, not a treatment recommendation.
When is an allogeneic (donor) stem cell transplant needed for AML?
It depends on risk and fitness. The NCI describes allogeneic transplant — using stem cells from a matched donor — as a central curative option for many AML patients once remission is achieved, most often for those whose disease is intermediate or high risk on cytogenetic and molecular testing, or whose leukemia has returned. It is intensive and carries real risks, so favorable-risk patients are sometimes treated with chemotherapy alone. Whether transplant fits your case is a decision for a hematology and transplant team, and a case review will tell you what your reports do and don't yet establish about donor options and timing.
How much does AML treatment cost in Istanbul?
There is no single figure, because the cost is driven by the length of the intensive induction and consolidation hospital stays, the transfusions and anti-infective care needed through the low-blood-count weeks, whether targeted drugs such as FLT3 or IDH inhibitors or venetoclax are added, and above all whether an allogeneic stem cell transplant is part of the plan — the transplant and its aftercare dominate the total. Istanbul typically runs well below Western-European prices for the same protocol, but every figure OncologyIstanbul™ publishes today is an illustrative placeholder pending verified partner-hospital quotes, itemized so you can check a real written quote line by line. See the Turkey Oncology Price Index for current ranges.
Start with a free 72-hour case review
Send your bone-marrow and molecular reports. Get a verified case file in your language — free, confidential, no obligation.
This page is general information, not medical advice. Medical facts are grounded in the U.S. National Cancer Institute; prices shown are illustrative placeholders pending verified partner-hospital quotes, not offers. Every cancer case is individual; assessments are based on the reports you provide and do not replace in-person examination.